Navigation Links
Niutang Recruits Seasoned Executive to Open U.K. Office
Date:6/23/2008

CHANGZHOU, China, June 23 /PRNewswire/ -- Niutang Chemical, a leading global manufacturer of food additives, pharmaceutical intermediates and curing agents, has recruited Alan Turner to lead its new office in the United Kingdom. As sales director of Niutang U.K. Ltd., Mr. Turner will spearhead all of Nuitang's sales and marketing in the U.K., including sweeteners and folic acid. He will particularly focus on the company's fast-growing businesses in aspartame and sucralose.

Mr. Turner brings a wealth of sales experience in the sweetener, pharmaceutical and chemical markets to Niutang. He has worked as key account manager for DSM's anti-infectives and specialty chemical products. He held a similar position with Holland Sweetener Company, which was one of the world's premier makers of aspartame.

"Alan is a strong addition to our experienced management team in Europe. He will play a pivotal role in continuing to strengthen Niutang's direct ties to our global customers," said Licheng Wang, Jr., general manager of Niutang. "Alan will continue to build our branded sweetener business in the U.K., where we are one of the largest suppliers of aspartame."

Mr. Turner also will be focusing on aggressively expanding Niutang's sucralose market share in the UK. Already a dominant sucralose supplier in the United States, the company recently received a "freedom to operate" legal opinion on its proprietary process for manufacturing sucralose for the U.K. and continental Europe.

"Our new U.K. office is part of Niutang's ongoing strategy to provide outstanding customer service, which is one of the qualities that distinguishes Niutang in the global marketplace," added Mr. Wang. "Our focus on adding value to all customer relationships, as well as maintaining the highest levels of integrity and meeting the most stringent manufacturing, compliance and quality benchmarks, has helped propel Niutang into one of the largest manufacturers of aspartame and sucralose in the world."

Mr. Turner reports to Donna Ling, vice president of sales of Changzhou Niutang Chemical. Mr. Turner assumes his new position July 01, and later this year, he will officially open the U.K. office in Birmingham.

About Niutang

Niutang Chemical is one of the world's leading manufacturers and distributors of food additives, chemicals and pharmaceutical intermediates that are instrumental to food, beverage, pharmaceutical, nutraceutical and industrial products. Established in 1969, Niutang's commitment to producing the highest-quality food additives at competitive prices has ensured its rapid growth into a leading global manufacturer of aspartame, folic acid, and more recently, sucralose. The company is certified in meeting the most stringent U.S. and European manufacturing, compliance and quality benchmarks. Based in China, Niutang also has sales and quality control operations in the United States and Europe that support its strong focus on quality, integrity and customer service.

For more information:

Doreen Lubeck

DJ Lubeck, LLC

773-583-4331

djlubeck@yahoo.com


'/>"/>
SOURCE Niutang Chemical
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Cleveland Clinic Recruits World Renowned Heart Rhythm Specialist to Direct Electrophysiology
2. Ascension Orthopedics Closes $21 Million Financing and Recruits an Orthopedics Industry Veteran as CEO
3. NexCore Group Opens Chicago Office Recruits New Hires
4. AT-TEN-TION!!! Fit Club Veterans Take on New Recruits in an All New Season of Celebrity Fit Club: Boot Camp Premiering Thursday, March 13 at 9PM ET/PT
5. ResMed Names Kieran Gallahue as Chief Executive Officer, Effective January 1, 2008.
6. Align Technology Executive to Present at Upcoming Financial Conferences
7. Mediware Names Thomas K. Mann Chief Executive Officer
8. PRA International Adds Dr. Susan Stansfield as Executive Vice President
9. STERIS Corporation Board of Directors Names Walter M. Rosebrough Jr. President and Chief Executive Officer
10. Karen Vigil Named Senior Vice President and Chief Executive Officer, Blue Shield of Californias Individual, Small Group, and Government Business Unit
11. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... ... February 05, 2016 , ... Boar’s Head Brand®, one of the ... this weekend’s Big Game. Take the stress out of your party preparation – follow ... happy at every stage of the game. , “The key to hosting a successful ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... CitiDent, announces that it is now welcoming orthodontist, Dr. Amanda Cheng, to ... a complete range of oral health care, including general dentistry, cosmetic treatments, periodontics, ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... ... Care for Patients with Rare Diseases, a continuing medical education (CME) event presented ... the first of its kind—and a first for ACCORD, whose mission is to ...
(Date:2/5/2016)... ... 05, 2016 , ... When one is tired of trying to cram belongings into spare space ... to rent a storage unit, but before hastily spending money on a unit, take these ... more space. But what one is often not told when utilizing these services are some ...
(Date:2/4/2016)... ... February 04, 2016 , ... True Health Initiative (THI), ... the creation of the THI Media Response Team (MRT). The primary mission of the ... and influencers about the fundamentals of healthy, sustainable eating, and other aspects of lifestyle ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... Feb. 4, 2016  SciClone Pharmaceuticals, Inc. (NASDAQ: ... has entered into a settlement agreement with the ... resolving the SEC,s investigation into possible violations of ... terms of the settlement agreement, SciClone has agreed ... disgorgement, pre-judgment interest and a penalty.  This payment ...
(Date:2/4/2016)... -- Global Immunology Market to 2022 - Large ... growth Summary Immune-mediated inflammatory diseases are ... affect 5–7% of western populations. Although they are ... key patient demographics, they are pathophysiologically linked, being ... inappropriate immune response. Generally, disease-modifying anti-rheumatic drugs, a ...
(Date:2/4/2016)...  Aethlon Medical, Inc. (Nasdaq: AEMD ), ... treat life-threatening diseases, today announced results for the ... 2015. --> --> ... our last quarterly call, we strategically advanced pre-clinical ... to establish the Aethlon Hemopurifier® as a leading ...
Breaking Medicine Technology: